-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Inclisiran is a double-stranded small interfering RNA that can inhibit the translation of the protoprotein-converting enzyme subtilisin-kexin type 9 (PCSK9) in the liver, thereby reducing low-density lipoprotein cholesterol (LDL-C) and other atherogenic factors Lipoprotein only needs to be used twice a year .
Inclisiran is a double-stranded small interfering RNA that can inhibit the translation of the protoprotein-converting enzyme subtilisin-kexin type 9 (PCSK9) in the liver, thereby reducing low-density lipoprotein cholesterol (LDL-C) and other atherogenic factors Lipoprotein, only need to use cholesterol twice a year
In October 2020, Inclisiran was recommended by the EU CHMP for approval for the treatment of adult patients with primary cholesterolemia (heterozygous family and non-familial) or mixed dyslipidemia.
FDA
The purpose of this study is to conduct a comprehensive patient-level analysis of Inlisiran's 3 Phase 3 studies (ORION-9, ORION-10, and ORION-11).
ORION-9 Inclisiran trial evaluated the effects of treatment of heterozygous familial hypercholesterolemia (HeFH) LDL-C patient; ORION-10 Inclisiran trial evaluated for atherosclerosis of medsci.
medsci.
Changes in LDL-C
Changes in LDL-CA total of 3660 patients were enrolled.
On day 510, the placebo-corrected change in LDL-C of the Inlisiran group was -50.
On the basis of the maximum tolerated dose of statins ± other LDL-C lowering drugs, Inlisiran, used twice a year, can reduce LDL-C in adult patients with the same risk of heterozygous familial hypercholesterolemia, ASCVD or ASCVD , Is an effective, safe and well-tolerated treatment.
Original source:
Wright R Scott, Ray Kausik K, Raal Frederick J et al.
org/10.
1016/j.
jacc.
2020.
12.
058" target="_blank" rel="noopener">Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis in this message
